# Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain

> **NCT04630990** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 117 (actual)

## Conditions studied

- Endometriosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04630990
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2024-03-26
- **Final completion:** 2024-03-26
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630990, "Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04630990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*